Laboratory Dynamics in Children With Mild Persistent Bronchial Asthma

Study Objective: to track the laboratory dynamics in children with mild persistent bronchial asthma (BA) at various stages of disease with or without baseline therapy. Study Design: prospective cohort study. Materials and Methods. The study included 42 patients with mild persistent BA aged 5 to 16 years. Each child was followed up for 3 years. At initiation of the study and during each visit, all patients had their blood eosinophils, nasal discharge (ND) and induced sputum (IS), as well as serum eosinophil cation protein (ECP) tested; and their respiratory function was assessed. All children were prescribed baseline therapy with low doses of inhalative glucocorticosteroids (GCS); 18 children also received allergen-specific immunotherapy (ASIT). Study Results. Inhalative GCS for BA exacerbations facilitated normalisation of sputum, ND and blood eosinophils. During periods of BA remission, ND and IS eosinophil levels increased, but patients did not have rhinitis and BA symptoms. Eosinophil levels in IS were higher vs. BA control (р = 0.05) and lower vs. disease exacerbations (р < 0.05). We did not find any differences in laboratory results in children with or without ASIT who were treated with low doses of inhalative and nasal GCS. Conclusion. Eosinophile inflammatory phenotype in patients did not charge depending on disease duration and control therapies. According to the study data, eosinophile levels in IS, when BA exacerbation was recorded, were 8.0% [3.0–16.0%]. This value can be used as an additional predictor for the need in increased therapy (a step forward). Irrespective of the disease stage and therapy, there was correlation between blood eosinophile level and IS eosinophile level and between IS eosinophile level and blood ECP concentration. Keywords: bronchial asthma, children, eosinophiles, induced sputum, inflammatory phenotype.

Download Full-text

Microbiota of Bronchial Tree in Children with Bronchial Asthma: today and 20 years ago

Doctor Ru ◽

10.31550/1727-2378-2021-20-10-25-30 ◽

2021 ◽

Vol 20 (10) ◽

pp. 25-30

Author(s):

I.A. Fedorov ◽

◽

O.G. Rybakova ◽

E.A. Goreva ◽

◽

...

Keyword(s):

Respiratory Tract ◽

Bronchial Asthma ◽

Lower Respiratory Tract ◽

Bronchial Tree ◽

Induced Sputum ◽

Cross Sectional ◽

Study Objective ◽

Study Results ◽

Inflammatory Phenotype ◽

Staphylococcus Spp

Study Objective: To analyze the microbiota of the lower respiratory tract in children with bronchial asthma, depending on the severity, period of the disease and inflammatory phenotype, as well as to compare the obtained data on the microbiota with the data obtained two decades ago. Study Design: The study is organized in a cross-sectional manner. Materials and Methods. The study involved 66 children with bronchial asthma aged 6 to 18 years old. All participants had their microbiota of the bronchial tree studied by bacteriological examination of induced sputum samples; in some children, the cytology of induced sputum was analyzed (n = 36). Statistical analysis was performed using Statistica 10.0. Intergroup differences in qualitative parameters were evaluated using χ2 and Fisher’s exact test. Statistically significant changes were are p < 0.05. Study Results. The predominant flora of the lower respiratory tract in children with bronchial asthma was Streptococcus spp. (66.7%), Staphylococcus spp. (33.3%) and Neisseria spp. (30.3%). There were no significant differences in the spectrum of the microflora of the bronchial tree depending on the period (exacerbation/remission) and the severity of the disease. When analysing the spectrum of the microbiota depending on the inflammatory phenotype, it was found that all sputum samples from patients with neutrophilic inflammatory phenotype were inoculated with Streptococcus spp., and in 25% of cases it was Streptococcus pneumonia. In patients with an eosinophilic inflammatory phenotype, most common was Staphylococcus spp. (75.0%), in particular Staphylococcus aureus (62.5%). When analysing the spectrum of microflora in a temporal aspect, it turned out that 20 years ago 41.2% of sputum samples did no demonstrate microflora growth. The growth of Streptococcus spp. and, in particular, Streptococcus pneumoniae, was significantly less frequent, Staphylococcus spp. were shown with the same frequency as now. Conclusion. The relationship between bronchial asthma and airway microbiota is complex and controversial. The revealed patterns show that the severity of bronchial asthma and the period of the disease do not affect the spectrum of microflora; however, statistically significant differences were found depending on the inflammatory phenotype. Since asthma phenotypes are immunological and physical-chemical characteristics of the mucous membrane of lower respiratory tract, this may be the reason for their selective impact of the microbial growth in respiratory tract, and on their biogeography, thus impacting the course and management of bronchial asthma. Keywords: bronchial asthma, respiratory tract microbiota, inflammatory phenotype, children.

Download Full-text

Design of a pivotal phase III trial of allergen specific immunotherapy (AIT) using a high-dose house dust mite (HDM) allergoid in patients with allergic bronchial asthma

10.26226/morressier.5acc8ad4d462b8028d89b144 ◽

2018 ◽

Author(s):

Michael Rudert ◽

Viola Gödicke

Keyword(s):

Bronchial Asthma ◽

House Dust ◽

House Dust Mite ◽

Specific Immunotherapy ◽

Phase Iii ◽

High Dose ◽

Pivotal Phase ◽

Allergen Specific Immunotherapy ◽

Phase Iii Trial ◽

Dust Mite

Download Full-text

CLINICAL SIGNIFICANCE OF SERUM CAVEOLIN-1 LEVELS IN GASTRIC CANCER PATIENTS

Experimental Oncology ◽

10.31768/2312-8852.2018.40(4):323-327 ◽

2018 ◽

Vol 40 (4) ◽

pp. 323-327 ◽

Cited By ~ 2

Author(s):

F Tas ◽

S Karabulut ◽

K Erturk ◽

D Duranyildiz

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Histological Grade ◽

Clinical Importance ◽

Disease Stage ◽

Control Group ◽

Tissue Samples ◽

Caveolin 1 ◽

Study Results ◽

Gastric Cancer Patients

Aim: Caveolin-1 plays a significant role in the pathogenesis of various carcinomas and its expression affects the survival of cancer patients. However, the molecular function of caveolin-1 and its possible clinical importance has remained uncertain in gastric cancer. No clinical trial has examined serum caveolin-1 levels in gastric cancer patients so far, instead all available results were provided from studies conducted on tissue samples. In the current study, we analyzed the soluble serum caveolin-1 levels in gastric cancer patients, and specified its associations with the clinical factors and prognosis. Material and Methods: Sixty-three patients with pathologically confirmed gastric cancer were enrolled into the trial. Serum caveolin-1 concentrations were detected by ELISA method. Thirty healthy subjects were also included in the study. Results: The median age of patients was 62 years, ranging from 28 to 82 years. The serum caveolin-1 levels in gastric cancer patients were significantly higher than those in control group (p < 0.001). The common clinical parameters including patient age, sex, lesion localization, histopathology, histological grade, disease stage, and various serum tumor markers (e.g. LDH, CEA, and CA 19.9) were not found to be associated with serum caveolin-1 levels (p > 0.05). Similarly, no correlation existed between serum caveolin-1 concentration and chemotherapy responsiveness (p = 0.93). Furthermore, serum caveolin-1 level was not found to have a prognostic role (p = 0.16). Conclusion: Even though it is neither predictive nor prognostic, serum caveolin-1 level may be a valuable diagnostic indicator in patients with gastric cancer. Key

Download Full-text

CLINICAL AND SPIROGRAPHIC FEATURES OF BRONCHIAL ASTHMA IN SCHOOLCHILDREN DEPENDING ON THE DIFFERENT REGIMENS OF BASIC ANTI-INFLAMMATORY THERAPY

Wiadomości Lekarskie ◽

10.36740/wlek202001105 ◽

2020 ◽

Vol 73 (1) ◽

Cited By ~ 1

Author(s):

Olena Koloskova ◽

Tetiana Bilous ◽

Galyna Bilyk ◽

Kristina Buryniuk-Glovyak ◽

Olena Korotun ◽

...

Keyword(s):

Bronchial Asthma ◽

Inhaled Corticosteroids ◽

Persistent Asthma ◽

High Specificity ◽

Clinical Feature ◽

Clinical Group ◽

Comparison Groups ◽

Anti Inflammatory ◽

High Doses ◽

Persistent Bronchial Asthma

The aim: To study the clinical and spirographic features persistence of the bronchial asthma in schoolchildren against the background of the alternative daily doses of inhaled corticosteroids to increase the effectiveness of anti-inflammatory therapy for this disease. Materials and methods: A complete comprehensive clinical-paraclinical examination of 65 schoolchildren with persistent asthma was conducted. According to the average daily dose of inhaled corticosteroids (ICS) the patients were divided into two clinical groups. The first (I) group consisted of 46 children who received ICS in the regimen of low-to-medium equipotent doses (253.95±9.98 μg per day), and the second (II) comparison group was formed of 19 patients who controlled the pBA using high doses of ICS (494.74±5.56 μg per day). Results: The patients of the І clinical group compared to patients of the ІІ group have a higher risk of the mild bronchial obstructive syndrome during asthma attacks. In assessing the level of control of persistent bronchial asthma using the CIA-scale, it was found that in II group cases of the controlled course of the disease were observed almost two times less than in children of the I group of comparison. In conducting spirography in children of comparison groups, it was shown that the ratio of indices of bronchospasm (FEV1/ FVC) was worse in patients receiving high doses of ICS. Conclusions: So, сharacteristic clinical feature of asthma controlled by high doses of ICS is more severe nature of bronchial obstructive syndrome during the period of exacerbation (OR=1.9-3.0). In the management of persistent bronchial asthma, the Gensler index which has high specificity (94.4%) and accuracy (92.2%) should be used for disease control verification.

Download Full-text

Eotaxin Level in Induced Sputum Is Increased in Patients with Bronchial Asthma and in Smokers

Respiration ◽

10.1159/000075205 ◽

2003 ◽

Vol 70 (6) ◽

pp. 600-605 ◽

Cited By ~ 17

Author(s):

Katsumaru Yamamoto ◽

Shingo Takanashi ◽

Yukihiro Hasegawa ◽

Yutaka Kanehira ◽

Mitsuaki Kaizuka ◽

...

Keyword(s):

Bronchial Asthma ◽

Induced Sputum

Download Full-text

Comparative Study of Eosinophils in the Blood and Induced Sputum during Bronchial Asthma

Bulletin of Experimental Biology and Medicine ◽

10.1023/b:bebm.0000024385.10506.f2 ◽

2004 ◽

Vol 137 (1) ◽

pp. 50-52

Author(s):

E. A. Gereng ◽

I. V. Sukhodolo ◽

R. I. Pleshko ◽

L. M. Ogorodova ◽

O. S. Kobyakova ◽

...

Keyword(s):

Comparative Study ◽

Bronchial Asthma ◽

Induced Sputum

Download Full-text

ASMANEX TWISTHALER - THE DRUG OF CHOICE AMONG INHALED CORTICOSTEROIDS

Rossiiskii Allergologicheskii ZHurnal ◽

10.36691/rja632 ◽

2013 ◽

Vol 10 (6) ◽

pp. 51-57

Author(s):

T V Latysheva ◽

E A Latysheva ◽

O V Shubina

Keyword(s):

Bronchial Asthma ◽

Inhaled Corticosteroids ◽

Control Methods ◽

Efficacy And Safety ◽

Prior Therapy ◽

Asthma Symptoms ◽

Drug Of Choice ◽

Systemic Corticosteroids ◽

Before And After ◽

Baseline Therapy

Goals. To reveal the clinical efficacy and safety of Asmanex in patients with moderate and severe bronchial asthma (BA), treated with inhaled and/or systemic glucocorticosteroids (GCS), depending on the severity and level of control. Methods. 40 patients (age 18 to 65 years) were treated with Asmanex with equivalent to prior therapy with inhaled corticosteroids (ICS) doses or in combination with systemic corticosteroids prior therapy (without increasing the dose of systemic corticosteroids) for 3 months. Efficacy was assessed before and after the treatment on a background of Asmanex treatment by the need of additional using of agonists of β 2-adrenoreceptors, severity of daytime and nighttime asthma symptoms, dynamics of spirometry parameters. The efficacy of Asmanex was compared with the original baseline therapy of other inhaled corticosteroids at equivalent doses using the new delivery system.

Download Full-text